ArticleFrontiers in immunology2026
Pyruvate kinase M2 is elevated in systemic sclerosis and plays a role in its pathogenesis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic sclerosis is an autoimmune fibrotic skin disease characterised by immune activation and fibrosis. Fibroblasts are at the core of this fibrotic process, differentiating into effector myofibroblasts; however, the drivers of this process remain obscure. Recently, metabolic changes in cells in fibrotic diseases have been uncovered, with changes in the TCA cycle and glycolysis being observed. Objective: The objective of this work was to elucidate the role of the glycolytic enzyme pyruvate kinase M2 (PKM2) in systemic sclerosis. Methods: Serum from early diffuse systemic sclerosis (SSc) patients and healthy controls (HC) was collected for PKM2 analysis by ELISA. Fibroblasts were isolated from HC and SSc biopsies and treated with transforming growth factor-beta 1 (TGF-β1) to assess PKM2 expression. PKM2 was pharmacologically modulated, and collagen and Extracellular Matrix (ECM) regulators were evaluated. Metabolic activity was assessed using Seahorse assays, and lactate transport was chemically inhibited. Chromatin immunoprecipitation was performed using a histone lactylation-specific or isotype antibody, and lactate or acetate supplementation experiments were conducted. Results: We found significantly elevated circulating and fibroblast PKM2 in SSc patients. Fibroblast PKM2 could be induced in healthy fibroblasts by TGF-β1 exposure. Furthermore, PKM2 drives a metabolic shift to glycolysis that can be blocked by forced tetramerisation of PKM2 from its dimeric form; this resulted in reduced ECM and matrix regulators. Mechanistically, PKM2-mediated glycolysis results in elevated lactate, which drives collagen via epigenetic regulation by histone H3K18 lactylation. Blockade of PKM2 dimerisation reduced Histone H3 at Lysine 18 (H3K18) lactylation at the collagen promoter, which could be restored with lactate but not acetate. We further demonstrated that lactate-induced collagen is partially mediated by HIF-1α. Conclusion: PKM2 drives activation of fibroblasts in SSc via metabolic changes such as glycolysis. Taking advantage of PKM2 tetramerisation or blockade of lactate generation could be a possible therapeutic option in a disease with few treatment options.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.